Sitemap   Home > Sitemap       Home     About Alpharma     Company Overview     Our Business Guidelines     Our Audit Committee Charter     Audit and Corporate Governance Committee Charter     Key Facts     History     Leadership Team     Alpharma Board of Directors     Headquarters Contact Information     Our Businesses     Businesses Overview     Investors' support     Electronic Investors Kit     Second Quarter 2008 Earnings Conference Call     Stock Price     SEC Filings     Proxy Statements     Annual Reports     Shareholder Account Information     Earnings Event Information     Corporate Profile     Headquarters Contact Information     Company Calendar     Business Development     Active Pharmaceutical Ingredients     Branded Products (Kadian)     Animal Health     Alpharma Worldwide     News Room     Press release archive     ALO Associate advisory     Careers     Make a Difference     Contact Us     Headquarters     Directions to Bridgewater     Business Divisions     News & Press Release archive     Alpharma To Expense Fees Related To Its April 2003 Note Issuance     Alpharma Announces Second Quarter 2003 Earnings Conference Call     Alpharma Declares Regular Quarterly Cash Dividend     Alpharma Posts Revised Presentation to Website     Alpharma Announces Revised Financial Expectations for the Second Half of 2003     Alpharma Announces Conference Call To Discuss Today's Press Release     Alpharma Corrects Previously Announced Cash Dividend Payable Date     Alpharma Declares Regular Quarterly Cash Dividend     FDA Grants Alpharma Final Approval For Gabapentin Capsules     Alpharma Granted Temporary Restraining Order on Extended Release Metformin Hydrochloride Tablets     Alpharma Reports Third Quarter 2003 Results     Alpharma Announces Third Quarter 2003 Earnings Conference Call     Court Extends Temporary Restraining Order on Metformin Hydrochloride Extened Release Tablets, 500mg     Court Extends Temporary Restraining Order On Metformin Hydrochloride Extended Release Tablets, 500mg     Court Extends Temporary Restraining Order on Metformin Hydrochloride Extended ReleaseTablets, 500mg     Court of Appeals Upholds FDA Award of Gabapentin Exclusivity to Alpharma     Alpharma Launches Clotrimazole & Betamethasone Dipropionate Topical Cream     Alpharma Declares Regular Quarterly Cash Dividend     Alpharma Announces Full Year 2003 Results     Alpharma Announces Fourth Quarter and Full Year Earnings Conference Call     Alpharma and Teva Enter Into Agreement Relating to Gabapentin     Alpharma Announces First Quarter 2004 Conference Call     Alpharma Declares Regular Quarterly Cash Dividend     Alpharma Announces Changes to its Board of Directors     Alpharma Announces First Quarter 2004 Results     Alpharma To Amend SEC Filings For Gain Contingency     Alpharma and MGI Pharma Enter Into Promotion Agreement For Kadian In Cancer Pain     ALPHARMA DECLARES REGULAR QUARTERLY CASH DIVIDEND     Alpharma Announces Second Quarter 2004 Results     Gabapentin Capsules Final FDA Approval Stayed     Alpharma Announces Second Quarter 2004 Conference Call     Court Vacates Stay on Gabapentin Capsules Launch     Alpharma Files Motion to Remove Stay on Gabapentin Capsule Launch     Alpharma Reaches Settlements Regarding Previously Disclosed FTC Investigation     Gabapentin Preliminary Injunction Hearing to Continue     Alpharma Announces Quarterly Dividend     Gabapentin Preliminary Injunction Request     Alpharma Receives Tentative FDA Approval for Metformin Hydrochloride 750mg Extended Release Tablets     Alpharma Receives FDA Approval for Metformin Hydrochloride 500mg Extended Release Tablets     Gabapentin Preliminary Injunction Hearing Rescheduled     Alpharma Announces That Pfizer Preliminary Injunction Request Is Denied     Court Denies Temporary Restraining Order on Gabapentin Capsules     Alpharma Launches Gabapentin Capsules     Alpharma Receives FDA Approval for Citalopram Hydrobromide Tablets     Alpharma Announces Third Quarter 2004 Conference Call     Alpharma Revises Third Quarter 2004 Guidance     Alpharma Launches Gabapentin Tablets     Alpharma Announces Third Quarter 2004 Results     FDA Grants Alpharma Final Approval and First to File Status for Gabapentin Tablets     Alpharma and Synthon Pharmaceuticals Announce Co-Promotion Agreement     Alpharma Declares Regular Quarterly Cash Dividend     Appeals Court Decision Leaves FDA's Award of Gabapentin Exclusivity To Alpharma Unchanged     Alpharma Settles Gabapentin Exclusivity Litigation     Alpharma Expects Conclusion of Ivax Gabapentin Litigation     Ronald Warner, Ph.D., Appointed President of Alpharma's Branded Business     Alpharma Announces Development and Manufacturing Agreement with Orchid     Alpharma Expects Goodwill Impairment Charge on U.S. Generics     Alpharma Launches Authorized Generic of MGI PHARMA's Salagaen® 5mg Tablets     Alpharma Announces Q4 Full Year Conference Call     Alpharma Delcares Regular Quarterly Cash Dividend     Alpharma Intends to Request 10-K Filing Extension     Alpharma Receives FDA Approval for Metformin Hydrochloride Extended Release Tablets, 750mg     Alpharma Announces Appointment of New Independent Accountants     Alpharma Announces 2004 Results     Alpharma to Amend SEC Filings     Alpharma Appoints Finn Berg Jacobsen to its Board of Directors     Alpharma Announces President and CEO Ingrid Wiik to Retire     Alpharma Announces First Quarter 2005 Results     Alpharma Receives FDA Approvable Status for Kadian® 200mg Capsules     Alpharma Announces First Quarter 2005 Conference Call     Alpharma Declares Regular Quarterly Cash Dividend     Alpharma Receives FDA Approval for Glyburide/Metformin HCI Tabelts     Alpharma Announces Agreement with Indian Firm Shasun to Develop and Manufacture Generic Prescription and API Products     Alpharma Reports Third Quarter 2005 Earnings Per Share of $0.34     Alpharma Reports Second Quarter 2005 Earnings Per Share of $0.38 Company Raises Full Year 2005 EPS Expectation     Frederick Lynch Named Senior Vice President of Alpharma Human Pharmaceuticals Supply Chain     Alpharma Announces First Quarter 2003 Earnings Conference Call     Alpharma Announces Agreement to Sell Senior Notes Due 2011     Alpharma Announces Proposed Private Placement of Senior Notes Due 2011     Alpharma Reports First Quarter 2003 DEPS of $0.15     Court Upholds FDA Award of Gabapentin Exclusivity to Alpharma     Alpharma Second Quarter Results Consistent With Guidance     Alpharma Elects New Members to its Board of Directors     Court Grants Alpharma Two Summary Judgments in its Gabapentin Litigation; Still Awaiting Court Decision On Last Remaining Patent     FDA Concludes Inspection at Alpharma Facility     Alpharma Reaches Agreement with Ivax regarding Metformin ER Tablets, 500mg     Alpharma Announces Sale of Aquatic Operations     United States Court of Appeals for 3rd Circuit Dismisses Class Action Lawsuit Against Alpharma     Alpharma to Amend Sec Filings For Previously Disclosed Items     Alpharma to Change KADIAN® Labeling     ALPHARMA Declares regular quarterly cash dividend     FDA Approves Alpharma’s BETAMETHASONE DIPROPIONATE AND CLOTRIMAZOLE CREAM     Alpharma announces results of Previously announced fda inspection     Alpharma receives fda approvable status for gabapentin TABLETS 600 mg and 800 mg     U.S. District Court Rules on Alpharma FDA Submission on Gabapentin     Alpharma Announces Plant Closings and Workforce Reductions Actions Part of Previously Announced Cost Cutting Initiatives     ALPHARMA Declares regular quarterly cash dividend     FDA Grants ALPHARMA 180 day market exclusivity for gabapentin capsules     Alpharma Announces Changes in its Human Pharmaceutical Organization     Alpharma announces Fourth Quarter and Full Year 2002 conference call     Alpharma Apppoints Michael Valentino President and Chief Operating Officer of New Global Human Pharmaceuticals Organization     Alpharma Announces Financial Expectations for 2003 Diluted Earnings Per Share Outlook is $1.15-$1.25     Alpharma announces conference call to discuss 2003 Guidance     Alpharma announces Third quarter 2002 conference call     Alpharma Appoints Jeffrey Campbell Vice President and Controller     ALPHARMA Declares regular quarterly cash dividend     Current news releases     Media Interviews

© Copyright 2007 Alpharma Inc. all rights reserved Contact Us Site Map Search